In This Article:
Those following along with Immunome, Inc. (NASDAQ:IMNM) will no doubt be intrigued by the recent purchase of shares by Clay Siegall, Chairman of the company, who spent a stonking US$999k on stock at an average price of US$7.29. Not only is that a big swing, but it increased their holding size by 20%, which is definitely great to see.
The Last 12 Months Of Insider Transactions At Immunome
In fact, the recent purchase by Chairman Clay Siegall was not their only acquisition of Immunome shares this year. They previously made an even bigger purchase of US$1.4m worth of shares at a price of US$13.91 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$6.26). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
While Immunome insiders bought shares during the last year, they didn't sell. The average buy price was around US$9.30. This is nice to see since it implies that insiders might see value around current prices. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
View our latest analysis for Immunome
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
Does Immunome Boast High Insider Ownership?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 3.3% of Immunome shares, worth about US$20m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
What Might The Insider Transactions At Immunome Tell Us?
It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Insiders likely see value in Immunome shares, given these transactions (along with notable insider ownership of the company). In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Immunome. Case in point: We've spotted 2 warning signs for Immunome you should be aware of, and 1 of these shouldn't be ignored.